

Patent Claims

1. Use of verapamil or verapamil derivatives for the inhibition of human tissue glucuronidase.
- 2.. Use according to claim 1 characterised in that, as
- 5 verapamil derivatives, there are used its R-enantiomer, metabolites of verapamil, gallopamil or chemically substituted derivatives of verapamil, gallopamil and its metabolites or its salts with pharmacologically compatible acids.
- 10 3. Use according to claim 1 or 2, characterised in that the R-enantiomers are used in pure form or, in comparison with the racemate, in enriched form.
- 4.. Use according to claim 1 to 3, characterised in that the glucuronidase inhibitor is used, with suitable
- 15 pharmacologically compatible adjuvants, orally or parenterally in normally liberating or controlled liberating form.
- 5.. Use according to claim 1 to 4, characterised in that the glucuronidase inhibitor is used alone for the
- 20 inhibition of β -glucuronidase in diseased tissue in order to prevent the progress of the disease, e.g. by inhibition of the tumour progression or the metastasis formation.
6. Use according to claim 1 to 4, characterised in that
- 25 the glucuronidase inhibitor is used for the stabilisation of metabolically-formed glucuronide conjugates of side-effect-rich active materials in order to reduce their side effects or to introduce a detoxification.
7. Use according to claim 1 to 4, characterised in that
- 30 the glucuronidase inhibitor is used combined with a glucuronide conjugate of an inflammation-inhibiting active material to be taken orally in order to protect this in the upper stomach-intestine tract against a cleavage and resorption and to activate in the deeper
- 35 lying intestinal sections by cleavage for the intestinal local therapy.

sub
A1

-15-

8. Use according to claim 1 to 4 for the improvement of the tissue-specific therapy, characterised in that the glucuronidase inhibitor, in the case of combined use with a glucuronide prodrug, protects this against
- 5 activation in healthy tissue in the case of maintenance of the activation in the target tissue.
9. Use according to claim 1 to 4 and 8, characterised in that, besides the glucuronidase inhibitor and the glucuronide prodrug, there is used combined beta-
- 10 glucuronidase bound to tissue-specific substances (e.g. antibodies, proteins, liposomes) in order to increase the activation of the prodrug in the target tissue and to protect the healthy tissue against the activation.

add
B1